GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
2.7k
c/orforglipron·posted 1 year ago by u/flair_enthusiast

my TSH moved and I cannot work out whether ACHIEVE is why

Question Receipts ×9 Sourced ×1 Cold Box ×1

my TSH moved and I cannot work out whether ACHIEVE is why — a position I have arrived at slowly and would like tested.

What is actually known, and what is being assumed.

Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its tolerability profile broadly resembles the class in the data published so far.

Assumed, frequently and confidently: that milligram comparisons with injectables mean something, that adherence is straightforwardly better because it is a tablet, that peptide purity discussions transfer to it. None of those hold. And nothing containing this compound is approved anywhere, which makes research-use-only material exactly that — not approved for human use.

Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.

It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.

Happy to answer the boring questions. Those are usually the ones worth asking.

2,831 up / 158 down95% upvoted45 commentsid 1742sl21 Dec 2024

45 comments

25 in this archive, depth 5

best — the order this archive was captured in

u/ravi_sandvik451 points·1 year ago

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

replysharereportpermalink
u/honest_syringe_maybe297 points·1 year ago

Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.

replysharereportpermalink
u/fabio_lehtinen204 points·1 year ago

Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.

replysharereportpermalink
u/lukas_delgado54 points·1 year ago

This. The absence of food and water timing restrictions is the practical difference people will actually notice.

replysharereportpermalink
u/hsa_math-13 points·1 year ago·edited

oral semaglutide is a peptide with an absorption enhancer, this is not that

replysharereportpermalink
u/trialwatch_theotrial nerd122 points·1 year ago

Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.

replysharereportpermalink
u/laila_delgado87 points·1 year ago

Right, and comparing milligrams between a small molecule and a peptide is meaningless in either direction.

replysharereportpermalink
u/throwaway_wl202660 points·1 year ago

Went looking for independent testing on this and found essentially nothing, which was clarifying.

replysharereportpermalink
u/incretin_ivyMOD37 points·1 year ago

Standing reminder: unapproved compound, research material is not for human use, and no schedules for other members.

replysharereportpermalink
u/flair_enthusiastOP19 points·1 year ago

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

replysharereportpermalink
[deleted]9 points·1 year ago

[deleted]

replysharereportpermalink
u/flair_enthusiastOP4 points·1 year ago

What did the tolerability table look like at that dose?

replysharereportpermalink
u/throwaway_wl20263 points·1 year ago

a non-peptide agonist does not degrade the way a peptide does

replysharereportpermalink
u/meera_sandvik2 points·1 year ago

That is a phase 2 result being quoted as though the programme had reported.

replysharereportpermalink
u/ahmed_okafor7 points·1 year ago

daily dosing changes adherence in both directions

replysharereportpermalink
u/meera_sandvik4 points·1 year ago

Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.

replysharereportpermalink
u/deleted_my_history33 points·1 year ago

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

replysharereportpermalink
u/flair_enthusiastOP24 points·1 year ago

ATTAIN and ACHIEVE are the programmes to keep straight

replysharereportpermalink
u/gustav_solberg6 points·1 year ago

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

replysharereportpermalink
u/incretin_ivypharmacology4 points·1 year ago

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

replysharereportpermalink
u/whois_wanda5 points·1 year ago

Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.

replysharereportpermalink
u/aksel_kjaer39 points·1 year ago

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

replysharereportpermalink
u/viktor_laurent17 points·1 year ago

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.

replysharereportpermalink
u/piotr_bruun23 points·1 year ago

Which programme and which readout are you quoting?

replysharereportpermalink
u/ewan_hovland6 points·1 year ago

the manufacturing story is genuinely different from the injectables

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.